Anti-PD1 Armored CD19 CAR-T Cells

· Jiangsu Topcel-KH Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Anti-PD1 Armored CD19 CAR-T Cells, covering 2026-01-28 to 2026-01-28. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma [Phase 1]

See pricing